Replies to post #770853 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Thanks Ex,

I'm no judge of whether any of these systems can do the job for us as well as the EDEN, you've made your point that other systems do exist.

I'm sure that LP has determined that we're best served by owning the system we're using, rather than paying someone else to use theirs, but that decision may have resulted in mass production delays, but no doubt will keep our cost lower.

Until we have more information about our EDEN system, I don't think it's possible to say if we have advantages, or not, over other such systems for production of certain personal products. From the manuscript you cited, it sounded like many companies are still making their approved products manually, or at least partially manually. I don't know how many of these systems have been tried and found to meet manufacturing needs in approved therapeutics.

Am I right in expecting that any product developed and approved with manual production must undergo the same sort of comparison trials when manufacturing is changed to one of these systems, even if the system has been approved for other products.

I think that if the EDEN is built to be monitored remotely for its operation, so NWBO can track every dose of vaccine produced, it may offer something the others may not. Clearly, I'm not certain of that. I just don't know if you purchased the device from someone else if you could monitor it's use, or if it would be done by whoever you purchase from, or perhaps not at all.

Gary

[The Danish Dude]

Yesteryears rehashing again ... aye ex?

Can you provide some more information about systems that could potentially be used to make DCVax-L vs. waiting for EDEN to be ready.

I have listed some before. This paper lists several.

Several ... yes ... that can not make DCvax-L.

This report takes a close look at the Flaskworks Eden 2.0 system. NWBO's automated manufacturing platform developed specifically for producing dendritic cell vaccines like DCVax-L.

Some investors have raised reasonable questions: Could Northwest Biotherapeutics have used a system already on the market? Is Flaskworks Eden genuinely different, or just another version of what other companies already offer?

The goal here is to provide straightforward answers, based on the biology of dendritic cells, the engineering behind Eden, and the patent protections in place.

The report explains why manufacturing DCVax-L is particularly complex, especially when it comes to harvesting fragile, adherent dendritic cells without damaging them. It also outlines how Flaskworks Eden was built to handle these challenges, and why general-purpose systems like CliniMACS Prodigy or the Cocoon platform fall short.

Finally, it shows how Flaskworks Eden fits into Northwest’s broader manufacturing and regulatory plans, including its role at the Sawston facility and its path toward commercial production.

If you're invested in NWBO or evaluating its long-term prospects, understanding Flaskworks Eden is essential.

Stating several competitors can do that, is not true. They clearly CAN NOT!

PDF FILE
Flaskworks Eden 2.0 vs competitors